25 results about "Mycoplasmata" patented technology

The invention belongs to the technical field of biology, and discloses application of a mycoplasma hyopneumoniae Ebh GA protein in preparation of mycoplasma hyopneumoniae or a multi-combined vaccine containing the mycoplasma hyopneumoniae. The applicant screens out the Ebh GA protein with immunogenicity from the mycoplasma hyopneumoniae for the first time, the Ebh GA protein is shown in SEQ ID NO.7 and can be used as a mycoplasma hyopneumoniae subunit vaccine, and therefore the applicant screens out the protein with immunogenicity of other pathogenic bacteria at the same time and combines the protein with the protein into a quadruple subunit vaccine. The antigens of the obtained quadruple vaccine have a synergistic effect, and compared with a single dose, the quadruple vaccine can enhance the immune effect of the quadruple vaccine.

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to an anti-mycoplasma pneumoniae antibody, a mycoplasma pneumoniae detection quality control product and a preparation method and application of the mycoplasma pneumoniae antibody and the mycoplasma pneumoniae detection quality control product. The invention provides an anti-mycoplasma pneumoniae antibody which comprises a light chain variable region and a heavy chain variable region, and the light chain variable region and the heavy chain variable region are specifically combined with a C-terminal immunodominance region of mycoplasma pneumoniae P1 protein. Wherein the C-terminal repeat region of the mycoplasma pneumoniae P1 protein is a core immunogenicity region, has high conservative property and strong immunogenicity, can induce a host to generate a specific IgM antibody in the early stage of infection, and is an ideal antibody target. The anti-mycoplasma pneumoniae antibody is obtained by screening through a phage display technology, has high affinity and high specificity, can effectively recognize the C-terminal immunodominance region of the mycoplasma pneumoniae P1 protein, and provides a reliable detection tool for early diagnosis of mycoplasma pneumoniae.

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The invention belongs to the technical field of quantitative detection of microorganisms, and particularly relates to a method for quantitatively detecting the viable count of mycoplasma bovis. The method for quantitatively detecting the viable count of the mycoplasma bovis is finally obtained by exploring the linear relation between the protein concentration and the viable count of multiple batches of mycoplasma bovis liquid samples after optimization of experimental conditions such as bacterium liquid preservation conditions, ultrasonic crushing modes, crushing duration and sample treatment modes, and the method is good in stability, high in timeliness and high in accuracy. The detection result is accurate, and a convenient and effective method is provided for rapid detection of the viable count of the mycoplasma bovis liquid.

The invention discloses a fusion protein for diagnosing mycoplasma bovis infection as well as a preparation method and application of the fusion protein. According to the fusion protein disclosed by the invention, dominant B cell epitope peptides of two strong immunogenic lipoproteins of mycoplasma bovis are connected, mycoplasma bovis infection can be effectively distinguished, and the fusion protein is further used for preparing a detection product for diagnosing mycoplasma bovis infection. A detection product prepared from the fusion protein disclosed by the invention has excellent sensitivity and specificity, and is of great significance for improving the economic benefit of the cattle breeding industry.

The invention discloses a pathogenic microorganism antigen passive agglutination semi-quantitative detection reagent and method based on sulfydryl modified gold nanoparticle covalent coupling, and belongs to the field of medical detection. According to the method, 50nm sulfydryl modified gold nanoparticles are used as a carrier, the 50nm sulfydryl modified gold nanoparticles and pathogenic microorganism antigens are subjected to sulfydryl-amino covalent coupling according to the mass ratio of 1: 50, accurate sealing through 0.5% BSA and centrifugal purification to prepare a 0.02 mg / mL liquid reagent, the antigen shedding rate is smaller than or equal to 5% after the liquid reagent is stored in a dark place at the temperature of 4 DEG C for 3 months, and the activity retention rate is larger than or equal to 97%. During detection, after serum is subjected to complement inactivation and dilution treatment and is incubated with the reagent at 37 DEG C for 1 hour, objective interpretation is realized by determining a semi-quantitative spectrum criterion that A650nm / A520nm is greater than or equal to 1.5, the sensitivity reaches 98.2%, and the specificity reaches 99.2%. The method can be popularized and applied to antibody detection of various pathogenic microorganisms such as mycoplasma pneumoniae and respiratory syncytial viruses, and the detection stability and objectivity are remarkably improved.

The invention discloses high-pathogenicity mycoplasma bovis and application thereof, and belongs to the technical field of microorganisms. The mycoplasma bovis is mycoplasma bovis, the number of the mycoplasma bovis is MbST201NMG1, and the mycoplasma bovis is registered in the China General Microbiological Culture Collection Center (CGMCC), and the registration number of the mycoplasma bovis is CGMCC No: 45661. The mycoplasma bovis provided by the invention is high in minimum inhibition concentration to antibiotics, low in adhesion rate to Mac-T cells but high in invasion rate, and can be used for establishing a more typical animal clinical lesion model of the mycoplasma bovis compared with other mycoplasma bovis, so that a certain support is provided for subsequent research and development of vaccines.

The invention discloses high-pathogenicity mycoplasma bovis and application thereof, and belongs to the technical field of microorganisms. The mycoplasma bovis is mycoplasma bovis, the number of the mycoplasma bovis is MbST202TJ6, and the mycoplasma bovis is registered in the China General Microbiological Culture Collection Center (CGMCC), and the registration number of the mycoplasma bovis is CGMCC No: 45662. The mycoplasma bovis provided by the invention has high minimum inhibition concentration to antibiotics, high adhesion rate to Mac-T cells but low invasion rate, can be used for establishing a more typical animal clinical lesion model of the mycoplasma bovis compared with other mycoplasma bovis, and provides certain support for subsequent research and development of vaccines.

The invention provides a mycoplasma pneumoniae vaccine and application thereof. Specifically, the invention relates to a mycoplasma pneumoniae protein, a vaccine composition composed of the mycoplasma pneumoniae protein, a preparation method and medical application of the mycoplasma pneumoniae protein, and the vaccine composition has a good protection effect on mycoplasma pneumoniae infection, and can remarkably relieve weight loss, reduce lung pathogen load and reduce lung pathological score. The mycoplasma pneumoniae vaccine has extremely high application value in mycoplasma pneumoniae vaccine development.

The invention relates to a culture medium for culturing human mycoplasma pneumoniae and a culture method, and belongs to the technical field of microorganisms, the culture medium for culturing the human mycoplasma pneumoniae comprises a mycoplasma culture medium and a growth promoting additive, the growth promoting additive comprises horse serum or fetal calf serum, cholesterol, penicillin sodium and an HEPES buffer solution, according to the culture medium for culturing the human mycoplasma pneumoniae, various components are simple and easy to obtain, the preparation method of the culture medium is greatly simplified, and the efficiency is improved; according to the culture method of the human mycoplasma pneumoniae, the culture mode is changed from a static state to a dynamic state, so that the culture efficiency of the human mycoplasma pneumoniae is improved, and meanwhile, the thallus yield of the human mycoplasma pneumoniae is also improved; the culture method for preparing the human mycoplasma pneumoniae is short in period, low in cost, high in culture viable organism density and high in yield, and is suitable for large-scale culture of the human mycoplasma pneumoniae.

The invention provides a mycoplasma bovis specific antigen epitope peptide and application thereof in antibody detection, and the amino acid sequence of the antigen epitope peptide is SEQ ID NO: 1. Bioinformatics prediction and serological verification are carried out on mycoplasma bovis immunogenic protein, the antigen epitope peptide highly associated with antibody reaction specificity is obtained through screening, a high-specificity mycoplasma bovis antibody detection method can be established by using the epitope peptide, the detection specificity is 100%, the sensitivity is 98.8%, and the detection time is short. And an effective tool is provided for serological diagnosis of mycoplasma bovis infection.

Provided are a Mycoplasma hyopneumoniae subunit vaccine, a preparation method therefor, and use thereof, which belong to the field of animal vaccines. The Mycoplasma hyopneumoniae subunit vaccine uses a Mycoplasma hyopneumoniae fusion protein as an antigen, the amino acid sequence of which is set forth in SEQ ID NO: 1. The preparation method comprises the following steps: (1) preparing an aqueous phase containing the fusion protein; and (2) mixing an oil phase and the aqueous phase according to a volume ratio of 1:0.8-1.2, and emulsifying to obtain the vaccine. The Mycoplasma hyopneumoniae subunit vaccine can protect pigs effectively for a long time and provides an effective means for the prevention and control of Mycoplasma hyopneumoniae.

The invention discloses a mycoplasma gallisepticum RRF recombinant protein, a polyclonal antibody and a preparation method thereof, and belongs to the technical field of gene engineering. The amino acid sequence of the recombinant protein is as shown in SEQ ID NO: 1. The preparation method comprises the following steps: (1) transforming a recombinant protein vector into a competent cell, and constructing an engineering bacterium with a recombinant vector; (2) IPTG (isopropyl-beta-d-thiogalactoside) induces the engineering bacteria, expression of mycoplasma gallisepticum RRF recombinant protein is performed, purification is performed, and the mycoplasma gallisepticum The polyclonal antibody is prepared by performing animal immunization by using mycoplasma gallisepticum RRF recombinant protein; the preparation method comprises the following steps: (1) immunizing animals by using mycoplasma gallisepticum RRF recombinant protein as an antigen; and (2) obtaining animal serum and purifying the animal serum. The anti-mycoplasma gallisepticum RRF polyclonal antibody disclosed by the invention can specifically recognize endogenous RRF protein of mycoplasma gallisepticum, is used for ELISA (Enzyme-Linked Immunosorbent Assay) and WesternBlot experiments, and provides a material basis for researching RRF functions.

The invention provides a mycoplasma pneumoniae polypeptide epitope with immunogenicity. The mycoplasma pneumoniae polypeptide epitope is a polypeptide epitope which is from mycoplasma pneumoniae type I and type II and adheres to key protein P1, P30, P40 / 90, P116 and / or CARDS toxin. The invention also provides a recombinant protein which contains more than one mycoplasma pneumoniae polypeptide epitope with immunogenicity. The invention further provides a vaccine for preventing mycoplasma pneumoniae infection, the vaccine provides protection against infection of at least one of mycoplasma pneumoniae type I and / or type II, and the vaccine is characterized by comprising the recombinant protein. According to the present invention, it is possible to provide a safe and effective vaccine for preventing mycoplasma pneumoniae infection.

The invention belongs to the technical field of biology, and particularly relates to application of a chicken early growth response factor-1 (EGR1) in resisting Mycoplasma gallisepticum (MG) infection, in particular to application of the EGR1 in resisting Mycoplasma gallisepticum (MG) infection. The invention finds that after MG infects chicken macrophages (HD11), the EGR1 expression level is obviously increased. After EGR1 is further overexpressed or interfered in cells, MG challenge discovers that overexpressed EGR1 can remarkably promote replication and adhesion of MG in the cells, and interference EGR1 can remarkably inhibit replication and adhesion of MG in the cells, inhibit release of proinflammatory factors and promote release of anti-inflammatory factors. The EGR1 is a susceptible gene of MG infection, and the MG resistance of cells can be remarkably improved by interfering the expression of the EGR1. Therefore, the expression of silent EGR1 gene is helpful for the body to resist MG infection, and a new molecular marker is provided for molecular marker-assisted selective breeding.

This invention relates to a novel fusion protein, immunogenic composition, recombinant vaccine, molecular architecture design, and applications for the prevention and treatment of Mycoplasma pneumoniae infection. The invention provides a novel fusion molecular architecture comprising fusion proteins encoded by the PstS and P37 genes, which can be used in the development of nucleic acid vaccines. The invention reveals that the novel fusion protein exhibits excellent immunogenicity, providing effective immune protection, significantly inhibiting Mycoplasma pneumoniae colonization, and, compared to nucleic acid vaccines encoding the P1-P30 fusion protein, which are known in the art to have excellent efficacy, demonstrates a more significant immune effect and protective effect against Mycoplasma pneumoniae infection, showing broad application prospects.

A Mycoplasma hyopneumoniae (Mhp) subunit vaccine and a preparation method and use thereof are provided. An antigen for the Mhp subunit vaccine is a fusion protein of Mhp, and has an amino acid sequence shown in SEQ ID NO: 1. The preparation method includes the following steps: (1) preparing an aqueous phase including the fusion protein; and (2) mixing an oil phase with the aqueous phase according to a volume ratio of 1:(0.8-1.2), and emulsifying to produce the vaccine. The Mhp subunit vaccine can effectively protect pigs in the long term, which provides an effective means for the prevention and control of mycoplasma pneumonia of swine.

The invention relates to the technical field of reagent detection, and discloses a chicken mycoplasma synoviae plate agglutination detection system as well as a detection method and application thereof. The detection sensitivity is improved, and the revolutionary breakthrough of the detection sensitivity is realized by constructing a'biotinylated recombinant antigen-streptavidin-color microsphere 'cascade signal amplification system; the detection specificity is high, cross misjudgment is effectively avoided, the high-purity and high-specificity genetic engineering recombinant p80 / vlhA fusion protein is adopted as a core recognition element, and interference of non-target impure protein is completely eradicated from an antigen source; the result interpretation is visual and objective, and the detection result is presented in the form of red particles or flocculent agglutination which can be clearly seen by naked eyes, and is clearly compared with a uniform red opacifying background.

The application provides a canine mycoplasma, a culture method and application thereof. A new canine mycoplasma is isolated, and the canine mycoplasma is named QAU241017.16 and preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 23, 2025, with a preservation number of CGMCC No. 46643. The isolated strain has 8 amino acid site mutations on a sialidase gene, and the animal experiment proves that the virulence is significantly enhanced. The inactivated vaccine prepared from the canine mycoplasma has good immunogenicity and safety, and can effectively stimulate the body to produce antibodies against the canine mycoplasma. The inactivated vaccine prepared based on the strain can induce a neutralizing antibody titer of 1:128. The application can provide a new scheme for the prevention and control of the canine mycoplasma. The canine mycoplasma isolation and culture method provided by the application is lower in cost, more efficient, and can realize rapid proliferation of the mycoplasma, so that a higher viable bacterial titer is achieved. Technical support is provided for the isolation and culture of the canine mycoplasma.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The application discloses a recombinant Mh-DnaK protein and application thereof in detection of porcine hemophilic mycoplasma, and discloses the recombinant Mh-DnaK protein with an amino acid sequence as shown in SEQ ID NO. 1. The application further discloses a porcine hemophilic mycoplasma antibody indirect ELISA detection kit and a detection method, wherein the above-mentioned recombinant Mh-DnaK protein is used as a coated antigen. The application establishes a porcine hemophilic mycoplasma antibody indirect ELISA detection method based on the recombinant Mh-DnaK protein, which is used for detecting porcine hemophilic mycoplasma antibody level, does not cross-react with part of other pig disease serum, has good specificity and repeatability, and provides an effective means for clinical diagnosis, epidemiological study and immune detection of Mycoplasma suis, Mycoplasma parvum and Mycoplasma haemosuis.

The application belongs to the technical field of nucleic acid aptamer, and provides an application of an aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein. The aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein is labeled with a fluorescent marker on a base sequence shown in SEQ.ID.NO.1. The nucleic acid aptamer obtained by the application has high specificity and high affinity for mycoplasma pneumoniae P1 adhesion protein, the Kd value is 392.8 nM, the linear detection range is 480-1200 nM, and the detection limit is 145.50 nM. The application can be used for visual detection of mycoplasma pneumoniae P1 adhesion protein, and has a good application prospect.

This invention relates to the field of medicinal chemistry, and more particularly to the application of truncated pleurotin derivatives in the preparation of therapeutic drugs for drug-resistant Mycoplasma gallisepticum infections. Through screening the obtained truncated pleurotin derivatives, this invention yielded compounds with significant inhibitory activity against tiamulin-resistant Mycoplasma gallisepticum. Oral administration experiments showed a cure rate of up to 70%, significantly superior to the same dose of tiamulin, demonstrating effective resistance overcoming and significant therapeutic efficacy. These truncated pleurotin derivatives, as novel veterinary drug formulations for the prevention and treatment of chronic respiratory diseases in chickens caused by Mycoplasma gallisepticum infection, provide an effective solution to the problem of Mycoplasma gallisepticum resistance.

The invention provides a cell preparation mycoplasma detection method and a kit thereof. The cell preparation mycoplasma detection method comprises the following steps: carrying out solid-liquid separation on a to-be-detected cell preparation to obtain cell precipitate; a cell lysis solution is added into the cell precipitate, cells are suspended in the lysis solution, then incubation is conducted for 15 min to 25 min at the room temperature, and the cell lysis solution comprises thiourea with the molar concentration of 0.8 mol / L to 1.8 mol / L; and carrying out nucleic acid extraction on the lysate. The extracted nucleic acid reacts with a qPCR reagent, then a fluorescent signal is collected through a fluorescent quantitative PCR instrument, and the PCR reaction process is monitored according to the change of the fluorescent signal. After the reaction is finished, testing to obtain a circulation threshold value, and judging whether the mycoplasma exists in the cell preparation or not according to the circulation threshold value. According to the method, the detection accuracy of the mycoplasma of the cell preparation can be effectively improved through thiourea-assisted testing.